MX2022000052A - Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766. - Google Patents
Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766.Info
- Publication number
- MX2022000052A MX2022000052A MX2022000052A MX2022000052A MX2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A
- Authority
- MX
- Mexico
- Prior art keywords
- increase therapeutic
- antineoplastic compound
- therapeutic compliance
- compliance
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962869389P | 2019-07-01 | 2019-07-01 | |
| PCT/US2020/040515 WO2021003279A1 (en) | 2019-07-01 | 2020-07-01 | System for enhancing therapeutic compliance of the anti-cancer compound e7766 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000052A true MX2022000052A (es) | 2022-04-06 |
Family
ID=71895194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000052A MX2022000052A (es) | 2019-07-01 | 2020-07-01 | Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12564600B2 (https=) |
| EP (1) | EP3993809B1 (https=) |
| JP (1) | JP7704690B2 (https=) |
| KR (1) | KR20220029717A (https=) |
| CN (1) | CN114599374A (https=) |
| AU (1) | AU2020300543A1 (https=) |
| BR (1) | BR112021026876A2 (https=) |
| CA (1) | CA3145824A1 (https=) |
| MX (1) | MX2022000052A (https=) |
| WO (1) | WO2021003279A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024533394A (ja) | 2021-09-09 | 2024-09-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｓｔｉｎｇアゴニストのバイオマーカー及びその使用方法 |
| CN115512788B (zh) * | 2022-09-16 | 2023-08-08 | 山东大学 | 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2446893A1 (en) * | 2010-11-01 | 2012-05-02 | Bergen Teknologioverføring AS | Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters |
| JP2015516423A (ja) | 2012-05-07 | 2015-06-11 | ノバルティス アーゲー | アリスポリビルによる薬物動態の調節 |
| PL3265565T3 (pl) | 2015-03-04 | 2021-01-25 | Board Of Regents, The University Of Texas System | Sposoby leczenia nowotworu z hemizygotyczną utratą tp53 |
| JP2019512233A (ja) | 2016-03-10 | 2019-05-16 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 |
| US20200055883A1 (en) * | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| KR102512494B1 (ko) | 2017-06-30 | 2023-03-22 | 교와 가부시키가이샤 | 의약 |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
-
2020
- 2020-07-01 MX MX2022000052A patent/MX2022000052A/es unknown
- 2020-07-01 JP JP2021578078A patent/JP7704690B2/ja active Active
- 2020-07-01 KR KR1020227003441A patent/KR20220029717A/ko active Pending
- 2020-07-01 US US17/597,199 patent/US12564600B2/en active Active
- 2020-07-01 CA CA3145824A patent/CA3145824A1/en active Pending
- 2020-07-01 CN CN202080061033.0A patent/CN114599374A/zh active Pending
- 2020-07-01 EP EP20750022.4A patent/EP3993809B1/en active Active
- 2020-07-01 BR BR112021026876A patent/BR112021026876A2/pt unknown
- 2020-07-01 WO PCT/US2020/040515 patent/WO2021003279A1/en not_active Ceased
- 2020-07-01 AU AU2020300543A patent/AU2020300543A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020300543A1 (en) | 2022-02-24 |
| JP2022538898A (ja) | 2022-09-06 |
| CN114599374A (zh) | 2022-06-07 |
| EP3993809B1 (en) | 2024-10-09 |
| EP3993809A1 (en) | 2022-05-11 |
| BR112021026876A2 (pt) | 2022-02-22 |
| KR20220029717A (ko) | 2022-03-08 |
| US12564600B2 (en) | 2026-03-03 |
| WO2021003279A1 (en) | 2021-01-07 |
| US20220304982A1 (en) | 2022-09-29 |
| CA3145824A1 (en) | 2021-01-07 |
| JP7704690B2 (ja) | 2025-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220008A1 (ar) | مثبطات parp1 | |
| AR109590A2 (es) | Régimen posológico para inhibidores de comt | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| CY1123571T1 (el) | Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| BR112022010633A2 (pt) | Composto de fórmula, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer de tireoide e invenção | |
| BR112018002342A2 (pt) | polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos | |
| JOP20220020B1 (ar) | مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة | |
| BR112022005657A2 (pt) | Dispositivo de distribuição de fármaco | |
| DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
| CY1116579T1 (el) | Φαρμακευτικες μορφες δοσολογιας ελεγχομενης απελευθερωσης | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| BR112022011998A2 (pt) | Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas | |
| CL2021001739A1 (es) | Inhibidores de la proteína de activación de fibroblastos. | |
| EA201000127A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
| EP4410373A3 (en) | Nucleic acid simultaneously inhibiting expression of mtor gene and stat3 gene | |
| MX2022000052A (es) | Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766. | |
| MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
| MX2022003639A (es) | Sistemas y métodos de suministro de fármacos. | |
| MX2020003665A (es) | Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo. |